Charles Lipsey, named as the 2013, 2017, and 2018 “Outstanding IP Litigator of the Year (Virginia)” at the Managing Intellectual Property Americas IP Awards, focuses his practice on intellectual property litigation, particularly patent infringement litigation.
Charles has handled cases covering a diverse spectrum of mechanical, chemical, and electrical technologies, with an emphasis on cases involving biotechnology and pharmaceutical chemistry. Since joining Finnegan in 1978, Charles has amassed a wealth of experience in patent infringement litigation, patent arbitration proceedings, and patent interferences. He is a Fellow of American College of Trial Lawyers.
The Legal 500 U.S. has recognized Charles’s distinguished career over the years, naming him one of the leading lawyers in patent litigation and inducting him into the patent litigation Hall of Fame. He has also been recognized by Intellectual Asset Management as a leading patent litigator in the D.C. area, and for his practice before the Federal Circuit.
Charles was also inducted into LMG Life Sciences’ Hall of Fame and recognized as “Hatch- Waxman (Branded) Litigator of the Year,” at the LMG Life Sciences Awards in 2013 and again in 2018. He has been ranked among top U.S. patent lawyers in Legal Media Group’s Guide to the World’s Leading Patent Law Practitioners since 2011. World IP Review recognized him as a WIPR Leader for patents in the United States.
Representative Experience:
- Lead counsel for Lilly in Hatch-Waxman patent infringement litigations against several ANDA filers seeking FDA approval to market generic versions of Eli Lilly’s Cymbalta®. The S.D. Indiana entered judgment before trial in favor of Eli Lilly and against all the ANDA filers on all issues, resulting in orders and judgment maintaining Cymbalta’s® market exclusivity through the end of its patent life.
- Represented AstraZeneca in Abbreviated New Drug Application (ANDA) litigation against Zydus on its Farxiga® pharmaceutical drug product. After a bench trial, Judge Andrews ruled that the defendant failed to prove that any of the patent claims at issue were invalid due to obviousness, resulting in a complete win for our client.
- Lead trial counsel for Avid in a suit concerning amyloid beta technology and its use in animal models in searching for drugs to treat Alzheimer’s disease (AD). Obtained jury verdict for Avid on issue of inventorship and patent ownership in 2012; affirmed by the Federal Circuit in 2013. Also obtained a finding of exceptional case, entitling Avid to an award of attorneys’ fees. The trial disposed of a series of suits by the AIA against numerous companies involved in scientific research relating to Alzheimer’s disease.
Updated Sep 2023
